TELOMERASE REVERSE TRANSCRIPTASE

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 15:15:09 UTC 2023` Edited by `admin` on `Sat Dec 16 15:15:09 UTC 2023`
Protein Type	ENZYME
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	NH2W5DQ1DO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TELOMERASE REVERSE TRANSCRIPTASE

Common Name

English

HUMAN TELOMERASE REVERSE TRANSCRIPTASE

Common Name

English

TELOMERASE-ASSOCIATED PROTEIN 2

Common Name

English

Code System Code Type Description

FDA UNII

NH2W5DQ1DO

Created by admin on Sat Dec 16 15:15:10 UTC 2023 , Edited by admin on Sat Dec 16 15:15:10 UTC 2023

PRIMARY

UNIPROT

O14746

Created by admin on Sat Dec 16 15:15:10 UTC 2023 , Edited by admin on Sat Dec 16 15:15:10 UTC 2023

PRIMARY

Related Record Type Details


					4GUY9L896T

HELENALIN

INHIBITOR -> TARGET

Comments:

Helenalin binds to Cys445 of telomerase in the Michael-type addition reaction, disturbing recognition of the telomere DNA at the telomerase active site and causing suppression of the enzyme activity.

Amount:


					55R7RG342O

TERTOMOTIDE

VACCINE ANTIGEN->TARGET


					6H8FDD5016

AS-1410

INHIBITOR -> TARGET

Comments:

One compound is a trisubstituted acridine compound AS1410, a close analogue of BRACO-19. Synergistic behaviour was observed in both cell lines (MCF7 and A549) with both compounds in combination with cis-platin, but only when the ratio of AS1410:cis-platin is >1. In vivo tumour xenograft studies with the A549 lung cancer model and the trisubstituted acridine compound AS1410 showed only a modest anti-tumour effect when administered alone, but produced rapid and highly significant decreases in tumour volume when administered in combination with cis-platin.